

ASX Announcement

8 July 2025

Cochlear receives FDA approval for the Cochlear™ Nucleus® Nexa™ System and Nucleus Kanso® 3 and Kanso® 3 Nexa Sound Processors

Cochlear Limited (ASX: COH) today announced that it has received regulatory approval for the Cochlear™ Nucleus® Nexa™ System and Nucleus Kanso® 3 and Kanso® 3 Nexa Sound Processors from the US Food and Drug Administration (FDA). Cochlear expects to launch the new products in the US by the end of the first quarter of FY26.

For further information, please contact:

Analysts

Kristina Devon
VP Corporate Strategy and Investor
Relations
kdevon@cochlear.com
Ph: + 61 2 9073 4194

Analysts

Cale Brown
Director Investor Relations
cbrown@cochlear.com
Ph: + 61 2 9072 2769

Media

Jennifer Stewart
VP Communications, Brand & Digital
Marketing
jstewart@cochlear.com
Ph: +61 2 9073 4186

This announcement is authorised by the Company Secretary.